نشر يوم 15. January 2015

Research on the therapy of cancer patients with thrombosis: Joint study by Vivantes and Charité begins

More than 15 percent of all patients with cancer develop thrombosis during the disease, with or without – sometimes fatal – pulmonary embolism. The current GECAT study aims to answer the question of how these patients are treated.

The cooperative project of Charité – Universitätsmedizin Berlin and the Vivantes hospital group is designed as a three-year registry study and is intended to provide information on possible improvements in the treatment of this serious complication.

In general, interactions between the tumor cell and the coagulation system are experimentally known and clinically provable. On average, tumor patients have an approximately sevenfold increased risk of thrombosis, depending on tumor type and other individual risk factors. This makes thrombosis the second leading cause of death in cancer patients.

In addition, epidemiological studies show that ten to fifteen percent of patients who experience a first spontaneous venous thromboembolism also have cancer without knowing it at the time. To date, there is little data on the medical care of these patients as their disease progresses. The GECAT study (German Evaluation of Cancer associated Thrombosis) will now investigate in more detail the reciprocal effect of cancer on the occurrence of thrombosis.

The study is being led by Dr. Robert Klamroth, Chief Physician of the Department of Internal Medicine – Angiology and Hemostaseology at Vivantes Friedrichshain Hospital: "The study is intended to show how hematological-oncological patients with venous thromboembolism are actually treated: With low-molecular-weight heparin, with vitamin K antagonists or the direct oral anticoagulants?" Whether and when to change therapy during the course of the disease will also be explored.

The study is being conducted in close collaboration with Prof. Dr. Hanno Riess, Medical Director of the Medical Clinic with a focus on hematology, oncology and tumor immunology at the Charité Mitte campus. Prof. Dr. Riess adds: "The oncology clinics of Charité and the oncology centers of Vivantes are participating in the study. In total, we want to collect and evaluate data from 350 patients. We expect reliable findings on how to improve therapy for this ever-growing group of patients."

Medical Care Centers (MVZ) turn 15!
Vivantes subsidiary celebrates anniversary
View event
Safer against tumors: Only department in Berlin that radiates completely without skin markings
Vivantes Neukölln Hospital: Innovative high-tech in radiation therapy
View event
Vivantes awarded by German Society for Thoracic Surgery!
Excellent Center for Thoracic Surgery
View event
Why Me?
View event
First Cancer Center recognized at Vivantes: When several organs are affected by cancer
Cancer Center Berlin-Neukölln certified by German Cancer Society
View event
Vivantes Neukölln Hospital opens state-of-the-art computed tomography center
More efficient diagnostics also for COVID-19 patients
View event
Visceral Oncology Center certified by German Cancer Society
Center for stomach cancer, pancreatic cancer and colorectal cancer at Vivantes Neukölln Hospital approved
View event
Application of the cooling cap for hair preservation during chemotherapy
Head skin cooling during chemotherapy
View event
Center at Vivantes Auguste-Viktoria Hospital receives award
German Cancer Society certifies interdisciplinary colorectal cancer center in Schöneberg
View event
The undetected
There are diseases that only become known because a celebrity is affected by them. One example is oral cavity carcinoma, which recently claimed the life of the well-known actor Jan Fedder. If it is discovered at an early stage, it is usually curable.
View event
Tumor conferences
Experts from different disciplines decide together
View event
High Volume, High Quality: Vivantes stands for premium medicine in the capital
View event
How naturopathy can support cancer therapy
View event
15th Berlin Cancer Congress starts on May 23, 2019 with patient day
The ten most common types of cancer treated at Vivantes
View event
German Cancer Society certifies interdisciplinary colorectal cancer center
Center at Vivantes Neukölln Hospital receives award
View event
Seal of approval for two interventional radiology centers
See inside the body and treat directly
View event
Life is not over
View event
A liver "that grows with its tasks"
View event
Not in the realm of shadows
View event
Side effects are no side issue: 14th Berlin Cancer Congress
View event
New team of chief physicians at the Vivantes Breast Center
View event